86
1. World Health Organization. The top 10 causes of death (2020).
https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
2. Fuster V. Global burden of cardiovascular disease: time to implement feasible
strategies and to monitor results. J Am Coll Cardiol. 2014;64(5):520-2.
3. Mackay J, Mensah G. Atlas of heart disease and stroke. World Health Organization;
2004:84–91.
4. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012
update: A report from the American Heart Association. Circulation.
2012;125(1):e12–e220.
5. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
6. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res.
2015;116:1509-1526.
7. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al.
Comparison of global estimates of prevalence and risk factors for peripheral artery
disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:13291340.
8. Hiatt WR, Armstrong EJ, Larson CJ, Brass EP. Pathogenesis of the limb
manifestations and exercise limitations in peripheral artery disease. Circ Res.
2015;116: 1527-1539.
9. Fokkenrood HJ, Bendermacher BL, Lauret GJ, Willigendael EM, Prins MH, Teijink
JA. Supervised exercise therapy versus non-supervised exercise therapy for
intermittent claudication. Cochrane Database Syst Rev. 2013;8: CD005263.
10. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates.
Clin Sci (Lond). 2018;132(12):1243-1252.
87
11. Firnhaber JM, Powell CS. Lower Extremity Peripheral Artery Disease: Diagnosis
and Treatment. Am Fam Physician. 2019;99(6):362-369.
12. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et
al. Supervised exercise versus primary stenting for claudication resulting from
aortoiliac peripheral artery disease: six-month outcomes from the claudication:
exercise versus endoluminal revascularization (CLEVER) study. Circulation.
2012;125: 130-139.
13. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for
claudication. N Engl J Med. 2002;347: 1941-1951.
14. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise
training on skeletal muscle histology and metabolism in peripheral arterial disease. J
Appl Physiol (1985). 1996;81:780-788.
15. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking
exercise versus strength training for patients with peripheral arterial disease.
Implications for the mechanism of the training response. Circulation. 1994;90:
1866-1874.
16. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with
Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131.
17. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic
M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk
(RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet
2021;397(10289):2060-2069.
18. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of
atherosclerosis. Nat Rev Drug Discov. 2011;10(5):365–376.
88
19. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and
clinical targets. Nat Med. 2002;8(11):1257–1262.
20. Powell DR, Gay JP, Smith M, et al. Fatty acid desaturase 1 knockout mice are lean
with improved glycemic control and decreased development of atheromatous
plaque. Diabetes Metab Syndr Obes. 2016;9:185–199.
21. Takagahara S, Shinohara H, Itokawa S, et al. A Novel Orally Available Delta-5
Desaturase Inhibitor Prevents Atherosclerotic Lesions Accompanied by Changes in
Fatty Acid Composition and Eicosanoid Production in ApoE Knockout Mice. J
Pharmacol Exp Ther. 2019;371(2):290–298.
22. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on musclederived interleukin-6. Physiol Rev. 2008;88:1379-1406.
23. Serrano AL, Baeza-Raja B, Perdiguero E, Jardí M, Muñoz-Cánoves P. Interleukin-6
is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell
Metab. 2008;7:33-44.
24. Toth KG, McKay BR, De Lisio M, Little JP, Tarnopolsky MA, Parise G. IL-6
induced STAT3 signalling is associated with the proliferation of human muscle
satellite cells following acute muscle damage. PLoS One. 2011;6: e17392.
25. Muñoz-Cánoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine
signaling in skeletal muscle: a double-edged sword? FEBS J. 2013;280: 4131-4148.
26. Sugo T, Terada M, Oikawa T, Miyata K, Nishimura S, Kenjo E, et al. Development
of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control
Release. 2016;237: 1-13.
89
27. Mahoney DJ, Parise G, Melov S, Safdar A, Tarnopolsky MA. Analysis of global
mRNA expression in human skeletal muscle during recovery from endurance
exercise. FASEB J. 2005;19: 1498-1500.
28. Yang Y, Creer A, Jemiolo B, Trappe S. Time course of myogenic and metabolic
gene expression in response to acute exercise in human skeletal muscle. J Appl
Physiol (1985). 2005;98(5):1745-52.
29. Cho HP, Nakamura M, Clarke SD. Cloning, expression, and fatty acid regulation of
the human delta-5 desaturase. J Biol Chem. 1999;274(52):37335–37339.
30. Matsuzaka T, Shimano H, Yahagi N, et al. Dual regulation of 5- and 6-desaturase
gene expression by SREBP-1 and PPAR. J Lipid Res. 2002;43(1):107–114.
31. Leonard AE, Kelder B, Bobik EG, et al. cDNA cloning and characterization of
human Delta5-desaturase involved in the biosynthesis of arachidonic acid. Biochem
J. 2000;347:719–724.
32. De Caterina R, Zampolli A. From asthma to atherosclerosis- 5-lipoxygenase,
leukotrienes, and inflammation. N Engl J Med. 2004:350(1):4–7.
33. Kwak JH, Paik JK, Kim OY, et al. FADS gene polymorphisms in Koreans:
association with ω6 polyunsaturated acids in serum phospholipids, lipid peroxides,
and coronary artery disease. Atherosclerosis. 2011;214(1):94–100.
34. Martinelli N, Girelli D, Malerba G, et al. FADS genotypes and desaturase activity
estimated by the ratio of arachidonic acid to linoleic acid are associated with
inflammation and coronary artery disease. Am J Clin Nutr. 2008;88(4):941–949.
35. Yashiro H, Takagahara S, Tamura YO, et al. A novel selective inhibitor of delta-5
desaturase lowers insulin resistance and reduces body weight in diet-induced obese
C57BL/6J mice. PLoS One. 2016;11(11):e0166198.
90
36. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arterioscler Thromb Vasc
Biol. 2006;26(2):242–249.
37. Nakashima Y, Plump AS, Raines EW, et al. ApoE-deficient mice develop lesions of
all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb.
1994;14(1):133–140.
38. Paigen B. Genetics of responsiveness to high-fat and high-cholesterol diets in the
mouse. Am J Clin Nutr. 1995;62(2):458S–462S.
39. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J
Physiol Pharmacol. 2004;55(3):503–517.
40. Veillard NR, Steffens S, Burger F, et al. Differential expression patterns of
proinflammatory and antiinflammatory mediators during atherogenesis in mice.
Arterioscler Thromb Vasc Biol. 2004;24(12):2339–2344.
41. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241.
42. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–
126.
43. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation.
2002;105(9):1135–1143.
44. Puntmann VO, Bigalke B, Nagel E. Characterization of the inflammatory phenotype
in atherosclerosis may contribute to the development of new therapeutic and
preventative interventions. Trends Cardiovasc Med. 2010;20(5):176–181.
45. Agren JJ, Julkunen A, Penttila I. Rapid separation of serum lipids for fatty acid
analysis by a single aminopropyl column. J Lipid Res. 1992;33(12):1871–1876.
46. Babaev VR, Chew JD, Ding L, et al. Macrophage EP4 deficiency increases
apoptosis and suppresses early atherosclerosis. Cell Metab. 2008;8(6):492–501.
91
47. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A (2) and
prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin
Invest. 2004;114(6):784–794.
48. Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient
mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment.
Circulation. 2005;112(4):578–586.
49. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the
development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc
Biol. 2004;24(2):369–375.
50. Ziboh VA, Miller CC, Cho Y. Metabolism of polyunsaturated fatty acids by skin
epidermal enzymes: generation of antiinflammatory and antiproliferative
metabolites. Am J Clin Nutr. 2000;71(1 Suppl):361S–366S.
51. Takai S, Jin D, Kawashima H, et al. Anti-atherosclerotic effects of dihomo-γlinolenic acid in ApoE-deficient mice. J Atheroscler Thromb. 2009;16(4):480–489.
52. Palumbo B, Oguogho A, Fitscha P, et al. Prostaglandin E1-therapy reduces
circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral
vascular disease. Vasa. 2000;29:179–185.
53. Takahashi HK, Iwagaki H, Tamura R, et al. Unique regulation profile of
prostaglandin E1 on adhesion molecule expression and cytokine production in
human peripheral blood mononuclear cells. J Pharmacol Exp Ther.
2003;307(3):1188–1195.
54. Wang X, Lin Y, Luo N, et al. Short-term intensive atorvastatin therapy improves
endothelial function partly via attenuating perivascular adipose tissue inflammation
92
through 5-lipoxygenase pathway in hyperlipidemic rabbits. Chin Med J (Engl).
2014;127(16):2953-9.
55. Darrow AL, Shohet RV, Maresh JG. Transcriptional analysis of the endothelial
response to diabetes reveals a role for galectin-3. Physiol Genomics.
2011;43(20):1144-52.
56. Martínez-Clemente M, Ferré N, González-Périz A, et al. 5-lipoxygenase deficiency
reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte
damage in hyperlipidemia-prone ApoE-null mice. Hepatology. 2010;51(3):817-27.
57. Witkowska AM. Soluble ICAM-1: a marker of vascular inflammation and lifestyle.
Cytokine. 2005;31(2):127–134.
58. Nguyen QM, Srinivasan SR, Xu JH, et al. Distribution and cardiovascular risk
correlates of plasma soluble intercellular adhesion molecule-1 levels in
asymptomatic young adults from a biracial community: the Bogalusa Heart Study.
Ann Epidemiol. 2010;20(1):53–59.
59. Marcinkowski M, Czarnecka D, Jastrzebski M, et al. Inflammatory markers 10
weeks after myocardial infarction predict future cardiovascular events. Cardiol J.
2007;14(1):50–58.
60. Rallidis LS, Zolindaki MG, Vikelis M, et al. Elevated soluble intercellular adhesion
molecule-1 levels are associated with poor short-term prognosis in middle-aged
patients with acute ischaemic stroke. Int J Cardiol. 2009;132(2):216–220.
61. Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1
accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb
Vasc Biol. 1999;19(6):1518–1525.
93
62. Ni W, Egashira K, Kitamoto S, et al. New anti-monocyte chemoattractant protein-1
gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice.
Circulation. 2001;103(16):2096–2101.
63. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, et al. Molecular and cellular
mechanisms linking inflammation to insulin resistance and β-cell dysfunction.
Transl Res. 2016;167(1):228–256.
64. Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic
syndrome. Transl Res. 2016;167(1):257–280.
65. Moon YA, Hammer RE, Horton JD. Deletion of ELOVL5 leads to fatty liver
through activation of SREBP-1c in mice. J Lipid Res. 2009;50(3):412–423.
66. Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of
gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc
Biol. 2010;30: 1535-1541.
67. Lotfi S, Patel AS, Mattock K, Egginton S, Smith A, Modarai B. Towards a more
relevant hind limb model of muscle ischaemia. Atherosclerosis. 2013;227: 1-8.
68. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The
prevention of progression of arterial disease and diabetes (POPADAD) trial:
factorial randomised placebo controlled trial of aspirin and antioxidants in patients
with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337: a1840.
69. He S, Zhao T, Guo H, Meng Y, Qin G, Goukassian DA, et al. Coordinated
Activation of VEGF/VEGFR-2 and PPARδ Pathways by a Multi-Component
Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in
Type 2 Diabetic Mice. PLoS One. 2016;11: e0167305.
94
70. Morimoto Y, Bando YK, Shigeta T, Monji A, Murohara T. Atorvastatin prevents
ischemic limb loss in type 2 diabetes: role of p53. J Atheroscler Thromb. 2011;18:
200-208.
71. White JP, Wrann CD, Rao RR, Nair SK, Jedrychowski MP, You JS, et al. G
protein-coupled receptor 56 regulates mechanical overload-induced muscle
hypertrophy. Proc Natl Acad Sci U S A. 2014;111: 15756-15761.
72. Norheim F, Langleite TM, Hjorth M, Holen T, Kielland A, Stadheim HK, et al. The
effects of acute and chronic exercise on PGC-1α, irisin and browning of
subcutaneous adipose tissue in humans. FEBS J. 2014;281: 739-749.
73. Catoire M, Mensink M, Boekschoten MV, Hangelbroek R, Müller M, Schrauwen P,
et al. Pronounced effects of acute endurance exercise on gene expression in resting
and exercising human skeletal muscle. PLoS One. 2012;7: e51066.
74. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy
metabolism in health and disease. J Clin Invest. 2006;116: 615-622.
75. Pearen MA, Muscat GE. Minireview: Nuclear hormone receptor 4A signaling:
implications for metabolic disease. Mol Endocrinol. 2010;24: 1891-1903.
76. Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of
interleukin-6 in metabolic regulation. Immunol Cell Biol. 2014;92: 331-339.
77. Yang Y, Creer A, Jemiolo B, Trappe S. Time course of myogenic and metabolic
gene expression in response to acute exercise in human skeletal muscle. J Appl
Physiol (1985). 2005;98(5): 1745-1752.
78. Bianchi L, Volpato S. Muscle dysfunction in type 2 diabetes: a major threat to
patient's mobility and independence. Acta Diabetol. 2016;53: 879-889.
95
79. Aragno M, Mastrocola R, Catalano MG, Brignardello E, Danni O, Boccuzzi G.
Oxidative stress impairs skeletal muscle repair in diabetic rats. Diabetes. 2004;53:
1082-1088.
80. McKay BR, Ogborn DI, Baker JM, Toth KG, Tarnopolsky MA, Parise G. Elevated
SOCS3 and altered IL-6 signaling is associated with age-related human muscle stem
cell dysfunction. Am J Physiol Cell Physiol. 2013;304: C717-C728.
81. Gopinath SD, Rando TA. Stem cell review series: aging of the skeletal muscle stem
cell niche. Aging Cell. 2008;7: 590-598.
82. Sala D, Zorzano A. Differential control of muscle mass in type 1 and type 2 diabetes
mellitus. Cell Mol Life Sci. 2015;72: 3803-3817.
83. D'Souza DM, Al-Sajee D, Hawke TJ. Diabetic myopathy: impact of diabetes
mellitus on skeletal muscle progenitor cells. Front Physiol. 2013;4: 379.
96
...
論文の公開元へ
